STAT

Priscilla Chan charts an ambitious, unglamorous course to fight disease. (Her husband is involved, too.)

In the Chan-Zuckerberg Initiative, critics see a goodwill tour to distract from Facebook’s sins. Fans see a thoughtful effort to build scaffolding that will prove critical to advancing science.
Priscilla Chan speaks in San Francisco.

SAN FRANCISCO — Dr. Priscilla Chan was just over a year out of her pediatric residency when, in 2016, she took the stage beside her spouse, Facebook founder Mark Zuckerberg, and pledged to affirmatively answer the question projected on the big screen behind them: “Can we cure all diseases in our children’s lifetime?”

It was the sort of absurdly ambitious question that would be easy to dismiss from a Silicon Valley technologist — the billionaire instantly recognizable in his gray T-shirt and jeans. But Chan, who grew up in the Boston suburbs, knew something about science. She had studied biology and worked in a neuroscience lab. She knew that the human body was more complicated than the most dizzyingly technical challenges her husband had overcome.

And yet.

Three and a half years later, Chan, who turns 35 this month, insists that the goal she and Zuckerberg have set for themselves — to “cure, prevent, or manage all diseases” by the year 2100 — is a realistic one.

“We are serious about it,” Chan told STAT in an interview. “We think that if that’s our north star, we think it’s not impossible.”

Today, Chan presides over the 400-person organization tasked with gradually giving away almost all of the couple’s fortune, which is currently worth about $80 billion. During a period in which her husband’s public image has been dented by a series of controversies involving privacy and disinformation, Chan has emerged as one of the most influential philanthropists in science — and as

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks